Zobrazeno 1 - 10
of 22
pro vyhledávání: '"K. Ueeda"'
Autor:
Hiromi Shimada, R. Wakiya, Hiroaki Dobashi, T. Miyagi, K. Sugihara, Shusaku Nakashima, Rina Mino, Mao Mizusaki, M. Kato, Norimitsu Kadowaki, Tomohiro Kameda, Mai Mahmoud Fahmy Mansour, K. Ueeda
Publikováno v:
Clinical rheumatology. 41(11)
In patients with systemic lupus erythematosus (SLE), a higher frequency of atherosclerotic lesions is associated with poor prognosis. Hydroxychloroquine (HCQ) has been reported to improve the lifespan and the prognosis of dyslipidaemia in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9f856bc4a27e6c6a98fa3bbdb92fd9
https://pubmed.ncbi.nlm.nih.gov/35849246
https://pubmed.ncbi.nlm.nih.gov/35849246
Autor:
R. Wakiya, K. Ueeda, H. Shimada, S. Nakashima, M. Kato, T. Miyagi, K. Sugihara, M. Mizusaki, R. Mino, T. Kameda, H. Dobashi
Publikováno v:
Annals of the Rheumatic Diseases. 81:1349-1350
BackgroundHydroxychloroquine (HCQ) therapy is recommended as a baseline treatment for all patients with systemic lupus erythematosus (SLE) due to its various benefits (1). However, it is not clear to what extent HCQ contributes to improvement in SLE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6dbdd8bfef8f801aaa6a0cc01001b285
https://doi.org/10.1136/annrheumdis-2022-eular.4140
https://doi.org/10.1136/annrheumdis-2022-eular.4140
Autor:
M. Kato, Hiroaki Dobashi, K. Ueeda, Nobuyuki Miyatake, Norimitsu Kadowaki, Tomohiro Kameda, M. Mahmoud Fahmy Mansour, T. Miyagi, Hiromi Shimada, Shusaku Nakashima, R. Wakiya
Publikováno v:
Lupus. 28:826-833
ObjectivesWe investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.MethodsSELENA-SLEDAI, Cutaneous Lupus Erythematou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::611adc6d6bc20b8d3ce1195066c6d016
https://doi.org/10.1177/0961203319846391
https://doi.org/10.1177/0961203319846391
Autor:
R. Wakiya, Y. Ushio, K. Ueeda, H. Shimada, S. Nakashima, M. Kato, T. Miyagi, K. Sugihara, M. Mizusaki, R. Mino, T. Kameda, H. Dobashi
Publikováno v:
Annals of the Rheumatic Diseases. 81:1020.1-1020
BackgroundApremilast has been shown to be effective in patients with Behçet’s disease (BD) in domains other than oral ulcers; however, its long-term efficacy is yet to be determined. Although serum cytokine modulation by increasing intracellular c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e4491065451c0b6bed4087896b4905b
https://doi.org/10.1136/annrheumdis-2022-eular.4181
https://doi.org/10.1136/annrheumdis-2022-eular.4181
Autor:
K. Ueeda, R. Wakiya, T. Miyagi, Hiromi Shimada, Tomohiro Kameda, M. Kato, Hiroaki Dobashi, Shusaku Nakashima, Mai Mahmoud Fahmy Mansour
Publikováno v:
Abstracts Accepted for Publication.
Background: Some reports revealed that S100A8 and S100A9 proteins were associated with disease activity of lupus nephritis(LN) [1]. However, there have been no reports about the mechanism of additional hydroxychloroquine (HCQ) treatment for systemic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::966ff314bd78fbd903e8668a41cd7066
https://doi.org/10.1136/annrheumdis-2019-eular.6457
https://doi.org/10.1136/annrheumdis-2019-eular.6457
Autor:
Y. Ushio, R. Senba, M. Kato, Tomohiro Kameda, M. Mizusaki, Hiroaki Dobashi, Hiromi Shimada, T. Miyagi, K. Sugihara, R. Wakiya, K. Ueeda, M. Mahmoud Fahmy Mansour, Shusaku Nakashima
Publikováno v:
Annals of the Rheumatic Diseases. 80:961.1-961
Background:Apremilast, the small-molecule phosphodiesterase (PDE) -4 inhibitor, was approved for the treatment of recurrent oral ulcers associated with Behcet’s disease (BD) in Japan from September 2019, following the success of the phase 3 RELIEF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9686ec5d7addddb9469bc5049b85fb11
https://doi.org/10.1136/annrheumdis-2021-eular.2772
https://doi.org/10.1136/annrheumdis-2021-eular.2772
Autor:
R. Wakiya, Y. Ushio, M. Mizusaki, Hiroaki Dobashi, K. Ueeda, M. Mahmoud Fahmy Mansour, M. Kato, T. Miyagi, Shusaku Nakashima, K. Sugihara, Hiromi Shimada, Tomohiro Kameda, R. Senba
Publikováno v:
Annals of the Rheumatic Diseases. 80:1169.2-1170
Background:In systemic lupus erythematosus(SLE), a higher frequency of atherosclerotic lesions is associated with a poor life prognosis (1). Hydroxychloroquine (HCQ) has been reported to improve the prognosis of life and dyslipidemia in SLE (2), and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a24ca522dc4b50efbab0bcef7abbf18
https://doi.org/10.1136/annrheumdis-2021-eular.2362
https://doi.org/10.1136/annrheumdis-2021-eular.2362
Autor:
Y. Ushio, Shusaku Nakashima, Hiroaki Dobashi, Hiromi Shimada, R. Wakiya, K. Ueeda, M. Mahmoud Fahmy Mansour, T. Miyagi, K. Sugihara, M. Kato, Tomohiro Kameda
Publikováno v:
Annals of the Rheumatic Diseases. 79:1495.2-1496
Background:HCQ for SLE in Japan has been administered in many cases after approval. Therefore, the effect of additional administration of HCQ on low disease activity of SLE was considered to be clearer.Objectives:To clarify the effect of HCQ treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebfeb7713b0a55b0dac9fbbc9204db63
https://doi.org/10.1136/annrheumdis-2020-eular.4149
https://doi.org/10.1136/annrheumdis-2020-eular.4149
Autor:
R Wakiya, T Kameda, K Ueeda, S Nakashima, H Shimada, M F Mansour, M Kato, T Miyagi, N Miyatake, N Kadowaki, H Dobashi
Supplmental Material for Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus by R Wakiya, T Kameda, K Ueeda, S Nakashima, H Shimada, M F Mansour, M Kato, T Miyagi, N Miyatake, N Kadowaki and H Dobashi in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f78a2fa381a79943c0c868f4f6e5671
Autor:
Hiroaki Dobashi, T. Miyagi, Hiromi Shimada, M. Kato, Norimitsu Kadowaki, Tomohiro Kameda, R. Wakiya, Shusaku Nakashima, A Kondo, K. Ueeda, M. Izumkawa
Publikováno v:
SLE, Sjögren’s and APS – treatment.
Background Systemic lupus erythematosus(SLE) is deeply associated with not only acquired immunity but also innate immunity throughout toll like receptors(TLRs) signalling. Among many TLRs, TLR7 and TLR9 were reported to be closely associated with IFN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b1daeb8dbbb88cbe43f596a146af42f
https://doi.org/10.1136/annrheumdis-2018-eular.2109
https://doi.org/10.1136/annrheumdis-2018-eular.2109